How Will the Market React to Esperion Therapeutics Inc (ESPR) Stock Getting a Bullish Rating

Esperion Therapeutics Inc (ESPR) stock is higher by 30.69% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Esperion Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ESPR!

See Full ESPR Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ESPR Stock Today?

Esperion Therapeutics Inc (ESPR) stock has risen 10.9% while the S&P 500 is down -0.02% as of 12:31 PM on Tuesday, Feb 6. ESPR is higher by $0.26 from the previous closing price of $2.38 on volume of 3,010,889 shares. Over the past year the S&P 500 is higher by 20.21% while ESPR is down -54.64%. ESPR lost -$2.37 per share in the over the last 12 months. To screen for more stocks like Esperion Therapeutics Inc click here.

More About Esperion Therapeutics Inc

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Click Here to get the full Stock Report for Esperion Therapeutics Inc stock.